Search

Introduction. Intramuscular hemorrhages are the second most common type of bleeding in patients with haemophilia. In haemophilic patients, muscle bleeding causes pain and postural defects and requires a long healing time. Aim. The purpose of this study is to evaluate the effectiveness of kinesiotaping, in combination with functional rehabilitation and CO2 laser therapy, in the healing process of MH in patients with haemophilia. Methods. We recruited 39 haemophilia patients who presented with a muscle hematoma. The patients were divided into 2 groups: treatment group treated with kinesiotaping, functional re-education and CO2 laser therapy, and a control group treated with functional re-education and CO2 laser therapy. The evolution of the hematoma was studied ultrasonographically and some evaluation scales (NRS, FISH) were administered. Results. The treatment group, compared to the control group, showed significant improvements in terms of: hematoma diameter (2.36 ± 3.32 vs 6.47 ± 3.37; p < 0.05), hematoma thickness (0.08 ± 0.12 vs 0.28 ± 0.14; p = 0.08), pain (NRS: 2 ± 1.57 vs 3.53 ± 1.37; p < 0.05) and number of days of replacement therapy (n days: 1.3 ± 0.48 vs 3.2 ± 0.98; p < 0.05). These results were shown to be superior in patients on prophylaxis. Conclusions. Kinesiotaping, associated with therapeutic exercise and physical therapy, can be a valuable aid in reducing the healing times of muscle hematomas in haemophilic patients, especially if already under prophylaxis.

Background: Despite recent improvements in survival due to advances in treatment, the quality of life of patients with lymphoma may be compromised by the long-term complications of chemotherapy and steroid therapy. Among these, a potentially relevant problem is bone loss and the development of fragility fractures.Aim: To provide further evidence of clinical or subclinical skeletal complications in correlation with biological variables and markers of bone disease in patients with complete response to therapy.Method: A cross-sectional observational study was conducted on subjects diagnosed with lymphoma with subsequent antineoplastic treatment, disease status after therapy defined as complete response disease for at least a year now. We performed: blood chemistry tests, imaging techniques (DEXA) and screening tools for the assessment of functional status and quality of life (SARC-F and mini-OQLQ).Results: Approximately 50% of the patients had osteoporosis. We found hypovitaminosis D and high PTH levels in most of the patients. We also found a high prevalence of vertebral fractures in 65.5% of cases. In the majority of patients, we found hypovitaminosis D and high levels of PTH. Furthermore, a statistically significant association between high PTH levels and previous lymphoma treatment. Finally, the Mini Osteoporosis Quality of Life questionnaire demonstrated a loss of quality of life as a consequence of the change in bone status.Conclusions: Patient treatment design for personalized chemotherapy would be desirable to reduce late effects on bone. Also, early prevention programs need to be applied before starting treatment. The most benefited subpopulations could be not only elderly but also young patients.

BACKGROUND: Aromatase inhibitors (AIs) might have a detrimental impact on bone health in breast cancer (BC) women. Denosumab has been shown to reduce the risk of fractures, but the appropriate time for starting is yet to be clearly defined. OBJECTIVE: To evaluate the effects of early treatment with Denosumab (⩽ 12 months after starting AIs) compared to a delayed treatment in BC women. METHODS: In this retrospective case-control study, we included medical records of BC post-menopausal women, treated with AIs therapy; they were divided as: study group (starting Denosumab ⩽ 12 months after AIs) and control group (> 12 months). At the baseline (T0) and at 18 months (T1), we evaluated the lumbar spine (LS) Tscore and femoral neck (FN) Tscore. Furthermore, at T1 we assessed the incident fragility fractures. RESULTS: Fifty-nine BC survivors (mean age: 61.5 ± 11.5 years) were included: 28 with Early Denosumab and 31 with Late Denosumab. At T1, the study group did not show any incident hip or vertebral fragility fracture, whereas the Late Denosumab group showed 2 incident hip fractures (6.5%) and 4 (12.9%) vertebral fragility fractures. Early Denosumab showed a significant positive effect on both LS (p= 0.044) and FN (p= 0.024) Tscore variations. CONCLUSION: Taken together, our findings suggest that an early start of Denosumab might be considered for the osteoporosis management in BC women undergoing AIs.